#CancerTreatment

EU Approves TEPKINLY® for Relapsed/Refractory Follicular Lymphoma MedEdge MEA

AbbVie recently announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment...

Read More
Menu
Categories
How does it work